Tsumura & Co.
TSMRF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.73B
Close$
$-7.75
133.4% downside
Current Fair Value
133.4% downsideOvervalued by 133.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.73 Billion |
|---|---|
| Enterprise Value | $72.01 Billion |
| Annual dividend | $1.00 |
| Dividend yield | 4.14% |
| Earnings per Share | $378.68 |
| Beta | 0.07 |
| Outstanding Shares | 74,545,980 |
Return
| Return on Equity | 9.34% |
|---|---|
| Return on Assets | 5.07% |
| Return on Invested Capital | 8.42% |
Valuation & Multiples
| P/E Ratio | 9.43 |
|---|---|
| PEG | 20.15 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | 0.36 |
| Enterprise Value to EBIT | 1.72 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 2.04 |
| Debt to Equity | 0.45 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$306.49 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$0.69
Consensus analyst estimateRevenue Estimate
$342.34 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Tsumura & Co.
4,923 employees
CEO: Terukazu Kato
Established in Tokyo, Japan, in 1893, Tsumura & Co. operates worldwide in the pharmaceutical sector. The company's core business involves the creation and international distribution of various medicinal products, with a particular focus ...